Amgen (NASDAQ: AMGN ) today announced data from the final analysis of the Phase 2 OCEAN(a)-DOSE study of olpasiran, a small interfering RNA (siRNA) during the Late-Breaking Science Session at the European Society of Cardiology (ESC) Annual Meeting being held in Amsterdam. In the off-treatment extension period, olpasiran showed a lasting effect on Lp(a) reduction nearly a year after the last dose.
Results from the OCEAN(a)-DOSE Phase 2 study announced in November of 2022 showed that doses of olpasiran ≥75 mg Q12W reduced patients' Lp(a) by >95% at week 36. The results from the off-treatment extension period show that patients previously dosed with ≥75 mg of olpasiran sustained a ~40-50% placebo-adjusted percent reduction in Lp(a) nearly a year after the last dose. No new safety concerns were identified during the off-treatment extension period.
"We are dedicated to reducing LDL cholesterol levels in people globally and continuing to pioneer ways to address the greatest risk factors in cardiovascular disease, including Lp(a). Worldwide, millions of people are at an increased risk of cardiovascular events due to elevated Lp(a) levels. Unfortunately, there are no approved medicines," said
Additionally, this study was the first to explore the effects of olpasiran on a key biomarker strongly associated with atherosclerosis, pro-atherogenic OxPL-apoB [Oxidized Phospholipids (Ox-PL) on apoB-100 (apoB)]. During the treatment period, olpasiran showed a dose-dependent reduction in pro-atherogenic OxPL-apoB.
"Additional results from the OCEAN(a)-DOSE study continue to be encouraging, as they tell us olpasiran not only robustly reduces Lp(a) levels, but that it has a long-lasting effect on this important risk factor for ASCVD," said
LDL Awareness to Action Implementation Consortium
Amgen is committed to working with stakeholders to achieve the goal of reducing cardiovascular disease globally and, this year at ESC, convened a new LDL Awareness to Action Implementation Consortium (LATAIC). LATAIC is focused on improving LDL-C testing and evidence-based treatment through identification of opportunities to accelerate efficiency and impact of the translation of evidence-based research into clinical practice. The consortium is comprised of leading CV institutions, including Duke, Harvard's BAIM Institute, Johns Hopkins, Geisinger, University of Colorado,
"I am proud to be working alongside Amgen and other cross disciplinary leaders in the cardiovascular space to increase LDL-C testing and implementation of evidence-based treatment, in order to tackle the urgent public health crisis of cardiovascular disease," said
For more information about the ESC abstracts, see below.
- RNA inhibition of Lp(a) with Olpasiran: Effects on Oxidized Phospholipids and Primary Results of the OCEAN(a)-DOSE Extension Program on Long-Term Efficacy and Safety
Saturday, Aug. 26, 4:45-5:00 pm CEST
- Cardiovascular Outcomes in Patients with Coronary Artery Disease and Elevated Lipoprotein(a): Implications for the OCEAN(a)-Outcomes Trial Population.
Sunday, Aug. 27, 10:55-11:05 am CEST
- Characteristics of patients initiating PCSK9i mAb following myocardial infarction and comparability of treatment groups in
Monday, Aug. 28, 2:15-3:00 pm CEST
- Improving risk stratification of recurrent myocardial infarction in a large real-world dataset using machine learning.
Saturday, Aug. 26, 11:15-12:00 pm CEST
Investigator-Sponsored Studies (ISS)
- Randomised trial of cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients.
Monday, Aug. 28, 11:30-11:45 am CEST
- Effect of evolocumab on platelet function in patients with acute coronary syndromes: An analysis of the randomized, double-blind, placebo-controlled EVOPACS Trial.
Monday, Aug. 28, 5:15-6:00 pm CEST
- PCSK9 inhibition with evolocumab decreases myocardial inflammation in individuals with acute coronary syndrome [EVACS data].
Saturday, Aug. 26, 2:00-2:10 pm CEST
- Lipoprotein(a) and the risk of Major Adverse Limb Events in Patients with Stable Atherosclerotic Vascular Disease [FOURIER/no evo data].
Saturday, Aug. 26, 11:15-12:00 pm CEST
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.